Results reporting for clinical trials led by medical universities and university hospitals in the Nordic countries was often missing or delayed

Author:

Nilsonne GustavORCID,Wieschowski Susanne,DeVito Nicholas J.ORCID,Salholz-Hillel Maia,Bruckner TillORCID,Klas KatarzynaORCID,Suljic TarikORCID,Yerunkar Samruddhi,Olsson NatashaORCID,Cruz Carolina,Strzebonska KarolinaORCID,Småbrekke LarsORCID,Wasylewski Mateusz T.,Bengtsson Johan,Ringsten MartinORCID,Schuster AminulORCID,Krawczyk TomaszORCID,Paraskevas ThemistoklisORCID,Ahnström Love,Raittio EeroORCID,Herczeg Luca,Hesselberg Jan-Ole,Karlsson SofiaORCID,Borana RonakORCID,Bruschettini MatteoORCID,Mulinari Shai,Lizárraga KarelyORCID,Siebert MaximilianORCID,Hildebrand NicoleORCID,Ramakrishnan Shreya,Janiaud PerrineORCID,Zavalis EmmanuelORCID,Franzen DelwenORCID,Boesen Kim,Hemkens Lars G.ORCID,Naudet FlorianORCID,Possmark SofieORCID,Willén Rebecca M.ORCID,Ioannidis John P.,Strech DanielORCID,Axfors Cathrine

Abstract

AbstractObjectiveTo systematically evaluate timely reporting of clinical trial results at medical universities and university hospitals in the Nordic countries.Study Design and SettingIn this cross-sectional study, we included trials (regardless of intervention) registered in the EU Clinical Trials Registry and/orClinicalTrials.gov, completed 2016-2019, and led by a university with medical faculty or university hospital in Denmark, Finland, Iceland, Norway, or Sweden. We identified summary results posted at the trial registries, and conducted systematic manual searches for results publications (e.g., journal articles, preprints). We present proportions with 95% confidence intervals (CI), and medians with interquartile range (IQR). Protocol:https://osf.io/wua3rResultsAmong 2,113 included clinical trials, 1,638 (77.5%, 95%CI 75.9-79.2%) reported any results during our follow-up; 1,092 (51.7%, 95%CI 49.5-53.8%) reported any results within 2 years of the global completion date; and 42 (2%, 95%CI 1.5-2.7%) posted summary results in the registry within 1 year. Median time from global completion date to results reporting was 698 days (IQR 1,123). 856/1,681 (50.9%) ofClinicalTrials.gov-registrations were prospective. Denmark contributed approximately half of all trials. Reporting performance varied widely between institutions.ConclusionMissing and delayed results reporting of academically-led clinical trials is a pervasive problem in the Nordic countries. We relied on trial registry information, which can be incomplete. Institutions, funders, and policy makers need to support trial teams, ensure regulation adherence, and secure trial reporting before results are permanently lost.What is new?-Many Nordic registered clinical trials were reported late or not at all.-Almost one in four trials remained unreported at the end of our search period.-About half of registered trials had reported results two years after completion.-Only 2% of trials posted summary results in the registry one year after completion.-Concerted action is needed to improve reporting of Nordic clinical trials.

Publisher

Cold Spring Harbor Laboratory

Reference56 articles.

1. Chalmers I , Glasziou P . Avoidable waste in the production and reporting of research evidence. The Lancet. 2009 Jul 4;374(9683):86–9.

2. World Health Organization. WHO Statement on public disclosure of clinical trial results [Internet]. 2015 [cited 2022 Aug 30]. Available from: https://www.who.int/news/item/09-04-2015-japan-primary-registries-network

3. Rationale for WHO's New Position Calling for Prompt Reporting and Public Disclosure of Interventional Clinical Trial Results

4. European Commission;Commission Guideline — Guidance on posting and publication of result-related information on clinical trials in relation to the implementation of Article 57(2) of Regulation (EC) No 726/2004 and Article 41(2) of Regulation (EC) No 1901/2006. Off J Eur Union,2012

5. US Food and Drug Administration. FDA. FDA; 2018 [cited 2022 Aug 30]. Food and Drug Administration Amendments Act (FDAAA) of 2007. Available from: https://www.fda.gov/regulatory-information/selected-amendments-fdc-act/food-and-drug-administration-amendments-act-fdaaa-2007

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Is full transparency in clinical trials an achievable goal?;European Journal of Internal Medicine;2024-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3